首页 > 最新文献

Journal of Clinical and Aesthetic Dermatology最新文献

英文 中文
Trichloroacetic Acid 15% Peel Alone versus in Combination with Microneedling in Patients with Acanthosis Nigricans. 15%三氯乙酸单独换肤与微针联合疗法在黑棘皮症患者中的应用。
Q2 Medicine Pub Date : 2024-04-01
Shrook A Khashaba, Salma Alaa, Fatma Eldeeb

Background: Acanthosis nigricans is a common hyperpigmentation disorder with a profound aesthetic impact. The primary concern of most patients is the cosmetic improvement, that is way there is a continuous search for the most effective cosmetic therapeutic option.

Methods: 40 acanthosis nigricans patients were included, lesions are split into equal halves; right side treated with TCA 15% peel and left side was treated with microneedling followed by TCA 15% peel, both sides were treated monthly for three months. Response to treatment was assessed by acanthosis nigricans grade improvement along with the percentage of improvement in texture and pigmentation individually.

Results: There was statistically significant improvement in acanthosis nigricans grade after treatment in both sides. The combination side showed more improvement in terms of texture and pigmentation.

Conclusion: Both TCA 15% alone or combined with microneedling were effective in improving acanthosis nigricans with superior results in combination modality.

背景:黑棘皮病是一种常见的色素沉着疾病,对美观有很大影响。方法:纳入 40 名黑棘皮病患者,将皮损分为两半,右侧使用 15% TCA 换肤,左侧使用微针治疗,然后使用 15% TCA 换肤,两侧每月治疗一次,为期三个月。通过黑棘皮病等级的改善以及质地和色素沉着改善的百分比来评估治疗反应:结果:两侧治疗后,黑棘皮病等级均有明显改善。结论:无论是单独使用 15%三氯乙酸,还是联合使用 15%三氯乙酸和 15%三氯乙酸,都能改善皮肤的质地和色素沉着:结论:无论是单独使用 15%三氯乙酸还是与微针疗法结合使用,都能有效改善黑棘皮病,而联合使用效果更佳。
{"title":"Trichloroacetic Acid 15% Peel Alone versus in Combination with Microneedling in Patients with Acanthosis Nigricans.","authors":"Shrook A Khashaba, Salma Alaa, Fatma Eldeeb","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Acanthosis nigricans is a common hyperpigmentation disorder with a profound aesthetic impact. The primary concern of most patients is the cosmetic improvement, that is way there is a continuous search for the most effective cosmetic therapeutic option.</p><p><strong>Methods: </strong>40 acanthosis nigricans patients were included, lesions are split into equal halves; right side treated with TCA 15% peel and left side was treated with microneedling followed by TCA 15% peel, both sides were treated monthly for three months. Response to treatment was assessed by acanthosis nigricans grade improvement along with the percentage of improvement in texture and pigmentation individually.</p><p><strong>Results: </strong>There was statistically significant improvement in acanthosis nigricans grade after treatment in both sides. The combination side showed more improvement in terms of texture and pigmentation.</p><p><strong>Conclusion: </strong>Both TCA 15% alone or combined with microneedling were effective in improving acanthosis nigricans with superior results in combination modality.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 4","pages":"28-32"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11022841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Cellulite to Post-liposuction Skin Irregularities: A Proposal for Definition and Classification. 从脂肪团到吸脂后皮肤不规则:关于定义和分类的建议。
Q2 Medicine Pub Date : 2024-04-01
Stefania Guida, Nicola Zerbinati, Claudio Conforti, Alessia Paganelli, Giovanni Pellacani, Hassan Galadari

Background: Post-liposuction skin irregularities (PLSI) represent a complication of liposuction, even though literature does not report specific data on their characteristics.

Objective: Considering the expanding request of treatment of PLSI and their similarities to cellulite, the aim of this study is to provide a definition or classification of their appearance according to a previously described cellulite scale and to highlight eventual novel features, in patients undergoing previous liposuction and a control group.

Methods: A total of 47 women, of which 47 percent performed a previous liposuction, were included in this study. Pictures of gluteal area and postero-lateral thighs were analyzed according to number and depth of depressions, skin laxity, asymmetry and v-sign by three investigators. The correlation between parameters and previous liposuction was explored with statistical analysis.

Results: Our results show good to excellent intraobserver agreement and moderate to good agreement between the evaluators. Additionally, we showed that PLSI can appear as marked cellulite signs (depth of evident depression) or as specific previously not reported features including asymmetry and v-sign.

Conclusion: Our findings provide information about the previously unreported morphology of PLSI. Further studies will apply validated features of PLSI proposed herein to clinical practice.

背景:吸脂术后皮肤不规则(PLSI)是吸脂术后的一种并发症,尽管文献中没有关于其特征的具体数据:考虑到 PLSI 治疗要求的不断扩大及其与橘皮组织的相似性,本研究的目的是根据之前描述的橘皮组织量表对其外观进行定义或分类,并突出曾接受过吸脂手术的患者和对照组的最终新特征:本研究共纳入了 47 名女性,其中 47% 曾进行过吸脂手术。三名研究人员根据凹陷的数量和深度、皮肤松弛程度、不对称程度和 V 形征对臀部和大腿后外侧的照片进行了分析。统计分析探讨了参数与之前吸脂手术之间的相关性:结果:我们的结果显示,观察者内部的一致性良好至极佳,评估者之间的一致性中等至良好。此外,我们还发现 PLSI 可表现为明显的橘皮组织迹象(凹陷深度明显),也可表现为以前未报道过的特定特征,包括不对称和 V 形征:结论:我们的研究结果提供了以前未报道过的 PLSI 形态学信息。进一步的研究将把本文提出的 PLSI 验证特征应用到临床实践中。
{"title":"From Cellulite to Post-liposuction Skin Irregularities: A Proposal for Definition and Classification.","authors":"Stefania Guida, Nicola Zerbinati, Claudio Conforti, Alessia Paganelli, Giovanni Pellacani, Hassan Galadari","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Post-liposuction skin irregularities (PLSI) represent a complication of liposuction, even though literature does not report specific data on their characteristics.</p><p><strong>Objective: </strong>Considering the expanding request of treatment of PLSI and their similarities to cellulite, the aim of this study is to provide a definition or classification of their appearance according to a previously described cellulite scale and to highlight eventual novel features, in patients undergoing previous liposuction and a control group.</p><p><strong>Methods: </strong>A total of 47 women, of which 47 percent performed a previous liposuction, were included in this study. Pictures of gluteal area and postero-lateral thighs were analyzed according to number and depth of depressions, skin laxity, asymmetry and v-sign by three investigators. The correlation between parameters and previous liposuction was explored with statistical analysis.</p><p><strong>Results: </strong>Our results show good to excellent intraobserver agreement and moderate to good agreement between the evaluators. Additionally, we showed that PLSI can appear as marked cellulite signs (depth of evident depression) or as specific previously not reported features including asymmetry and v-sign.</p><p><strong>Conclusion: </strong>Our findings provide information about the previously unreported morphology of PLSI. Further studies will apply validated features of PLSI proposed herein to clinical practice.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 4","pages":"24-27"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11022845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines. 整合 40-GEP 测试,改进皮肤鳞状细胞癌辅助放射治疗的临床建议:多学科共识指南。
Q2 Medicine Pub Date : 2024-03-01
Ramesh Gopal, Michael Marquardt, Gaurav Singh, Stanislav N Tolkachjov, Sarah T Arron

Early identification and intervention in patients with cutaneous squamous cell carcinoma (cSCC) who are at high risk for metastasis is important for optimal outcomes. Prognostic tools (e.g., American Joint Committee on Cancer, 8th edition [AJCC-8]) and management guidelines (National Comprehensive Cancer Network® [NCCN]) are useful in helping to identify high-risk patients with cSCC who might benefit from adjuvant therapies, such as radiation and/or immunotherapies; however, traditional staging and management guidelines rely on clinicopathologic risk factors to predict risk, which limits their prognostic accuracy. Gene expression profiling (GEP) is a clinically available, objective metric that can be used in conjunction with traditional clinicopathological staging to help clinicians stratify risk in patients with cSCC. The validated 40-GEP test can accurately classify patients with at least one high-risk feature as being at low (Class 1), higher (Class 2A), or highest (Class 2B) biological risk of nodal or distant metastasis within three years of diagnosis. A multidisciplinary panel comprising radiation oncologists and dermatologists/Mohs micrographic surgeons with expertise in cSCC management convened in June 2023 to discuss the utility of 40-GEP testing in cSCC clinical decision-making in regard to adjuvant radiation therapy (ART). The panel identified gaps in clinical practice in which 40-GEP testing has particular utility: in escalation of care for lower-stage patients with high-risk tumors; in de-escalation of care for patients for whom the risks of ART may outweigh the benefits; and in decision-making regarding elective radiation to the nodal basin. The expert panel developed a risk-based clinical workflow for ART in patients with cSCC, utilizing 40-GEP testing within NCCN management guidelines and AJCC-8 staging.

皮肤鳞状细胞癌(cSCC)患者如果有转移的高风险,早期识别和干预对获得最佳治疗效果非常重要。预后工具(如美国癌症联合委员会第八版 [AJCC-8])和管理指南(美国国家综合癌症网络® [NCCN])有助于帮助识别可能从放射和/或免疫疗法等辅助疗法中获益的高危 cSCC 患者;然而,传统的分期和管理指南依赖临床病理风险因素来预测风险,这限制了其预后的准确性。基因表达谱分析(GEP)是一种临床可用的客观指标,可与传统的临床病理分期结合使用,帮助临床医生对 cSCC 患者进行风险分层。经过验证的 40-GEP 检测能准确地将至少具有一种高危特征的患者分为低危(1 级)、高危(2A 级)或最高危(2B 级),以确定其在诊断后三年内发生结节或远处转移的生物学风险。2023 年 6 月,一个由放射肿瘤专家和皮肤科专家/Mohs 显微外科专家组成的多学科小组召开会议,讨论 40-GEP 检测在 cSCC 辅助放射治疗(ART)临床决策中的作用。专家组确定了 40-GEP 检测在临床实践中具有特殊作用的不足之处:对低分期高危肿瘤患者进行升级治疗;对 ART 风险可能大于益处的患者进行降级治疗;以及对结节盆地进行选择性放射治疗的决策。专家组制定了基于风险的 cSCC 患者 ART 临床工作流程,在 NCCN 管理指南和 AJCC-8 分期中使用 40-GEP 检测。
{"title":"Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.","authors":"Ramesh Gopal, Michael Marquardt, Gaurav Singh, Stanislav N Tolkachjov, Sarah T Arron","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Early identification and intervention in patients with cutaneous squamous cell carcinoma (cSCC) who are at high risk for metastasis is important for optimal outcomes. Prognostic tools (e.g., American Joint Committee on Cancer, 8th edition [AJCC-8]) and management guidelines (National Comprehensive Cancer Network® [NCCN]) are useful in helping to identify high-risk patients with cSCC who might benefit from adjuvant therapies, such as radiation and/or immunotherapies; however, traditional staging and management guidelines rely on clinicopathologic risk factors to predict risk, which limits their prognostic accuracy. Gene expression profiling (GEP) is a clinically available, objective metric that can be used in conjunction with traditional clinicopathological staging to help clinicians stratify risk in patients with cSCC. The validated 40-GEP test can accurately classify patients with at least one high-risk feature as being at low (Class 1), higher (Class 2A), or highest (Class 2B) biological risk of nodal or distant metastasis within three years of diagnosis. A multidisciplinary panel comprising radiation oncologists and dermatologists/Mohs micrographic surgeons with expertise in cSCC management convened in June 2023 to discuss the utility of 40-GEP testing in cSCC clinical decision-making in regard to adjuvant radiation therapy (ART). The panel identified gaps in clinical practice in which 40-GEP testing has particular utility: in escalation of care for lower-stage patients with high-risk tumors; in de-escalation of care for patients for whom the risks of ART may outweigh the benefits; and in decision-making regarding elective radiation to the nodal basin. The expert panel developed a risk-based clinical workflow for ART in patients with cSCC, utilizing 40-GEP testing within NCCN management guidelines and AJCC-8 staging.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3 Suppl 2","pages":"S3-S8"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10939503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Prospective, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of a Cream Containing Xyloglucan, Pea Protein, and Opuntia ficus-indica Extract Versus Calcipotriol/Betamethasone in Adult Patients with Mild-to-moderate Psoriasis. 一项前瞻性、多中心、开放标签研究,旨在评估含有木聚糖、豌豆蛋白和鸦胆子提取物的乳霜与卡泊三醇/倍他米松对轻度至中度银屑病成人患者的安全性和有效性。
Q2 Medicine Pub Date : 2024-03-01
Stefano Veraldi, Valentina Rosca, Remus Ioan Orasan, Magda Constantin, Roni P Dodiuk-Gad

Objective: Psoriasis is a chronic, inflammatory skin disease, requiring local and systemic drugs according to disease severity. This study aims to investigate the efficacy and safety of a topical treatment containing xyloglucan, pea proteins and Opuntia ficus-indica extracts (XPO) compared to calcipotriol 50mcg/betamethasone 0.5mg ointment (CB).

Methods: Forty-two patients diagnosed with mild-to-moderate plaque psoriasis were assigned 1:1 to XPO treatment or CB for 28 days. Disease status was assessed at baseline (V1), monitored every two weeks (V2, V3), and at follow-up (V4). Disease severity was assessed by PASI (Psoriasis Area and Severity Index), PGA (Physician's Global Assessment), and VAS (Visual Analog Scale for itching). Photos were taken before and after XPO treatment. Treatment efficacy was determined by comparing psoriasis severity at baseline to V3. Tolerability was assessed by monitoring the occurrence of adverse events.

Results: Both groups showed a statistically significant difference in PASI score from V1 to V2 (p=0.001, XPO; p=0.008, CB) and to V3 (p=0.001, XPO; p=0.004, CB). XPO achieved a PASI 50 score of 24 percent at V2 and 52 percent at V3 compared to CB (0% at V2 and 19% at V3). At V3, PGA was significantly reduced in both groups (p=0.003, XPO; p=0.001 CB). Both treatments significantly reduced itching at V2 (p=0.001, XPO; p=0.003, CB) and V3 (p=0.001, XPO; p=0.0005, CB).

Conclusion: XPO showed similar efficacy to CB, significantly reducing disease severity, erythema, itching, induration, and scaling with an excellent tolerability profile.

目的:银屑病是一种慢性炎症性皮肤病,根据病情严重程度需要局部和全身用药。本研究旨在探讨含有木聚糖、豌豆蛋白和鸦胆子提取物的外用疗法(XPO)与钙泊三醇 50 毫克/倍他米松 0.5 毫克软膏(CB)相比的疗效和安全性:42名被诊断为轻度至中度斑块状银屑病的患者按1:1的比例被分配到XPO治疗或CB治疗28天。在基线(V1)、每两周监测一次(V2、V3)和随访(V4)时对疾病状态进行评估。疾病严重程度通过 PASI(银屑病面积和严重程度指数)、PGA(医生总体评估)和 VAS(瘙痒视觉模拟量表)进行评估。在 XPO 治疗前后拍摄照片。治疗效果通过比较基线与 V3 的牛皮癣严重程度来确定。通过监测不良反应的发生情况来评估耐受性:两组患者的 PASI 评分从 V1 到 V2(P=0.001,XPO;P=0.008,CB)和 V3(P=0.001,XPO;P=0.004,CB)均有显著统计学差异。与 CB(V2 为 0%,V3 为 19%)相比,XPO 在 V2 的 PASI 50 得分为 24%,在 V3 为 52%。在 V3 期,两组的 PGA 均显著降低(XPO,p=0.003;CB,p=0.001)。在 V2(P=0.001,XPO;P=0.003,CB)和 V3(P=0.001,XPO;P=0.0005,CB)时,两种疗法都能明显减轻瘙痒:XPO显示出与CB相似的疗效,能显著减轻疾病的严重程度、红斑、瘙痒、压痕和脱屑,且耐受性极佳。
{"title":"A Prospective, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of a Cream Containing Xyloglucan, Pea Protein, and <i>Opuntia ficus-indica</i> Extract Versus Calcipotriol/Betamethasone in Adult Patients with Mild-to-moderate Psoriasis.","authors":"Stefano Veraldi, Valentina Rosca, Remus Ioan Orasan, Magda Constantin, Roni P Dodiuk-Gad","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Psoriasis is a chronic, inflammatory skin disease, requiring local and systemic drugs according to disease severity. This study aims to investigate the efficacy and safety of a topical treatment containing xyloglucan, pea proteins and <i>Opuntia ficus-indica</i> extracts (XPO) compared to calcipotriol 50mcg/betamethasone 0.5mg ointment (CB).</p><p><strong>Methods: </strong>Forty-two patients diagnosed with mild-to-moderate plaque psoriasis were assigned 1:1 to XPO treatment or CB for 28 days. Disease status was assessed at baseline (V1), monitored every two weeks (V2, V3), and at follow-up (V4). Disease severity was assessed by PASI (Psoriasis Area and Severity Index), PGA (Physician's Global Assessment), and VAS (Visual Analog Scale for itching). Photos were taken before and after XPO treatment. Treatment efficacy was determined by comparing psoriasis severity at baseline to V3. Tolerability was assessed by monitoring the occurrence of adverse events.</p><p><strong>Results: </strong>Both groups showed a statistically significant difference in PASI score from V1 to V2 (<i>p</i>=0.001, XPO; <i>p</i>=0.008, CB) and to V3 (<i>p</i>=0.001, XPO; <i>p</i>=0.004, CB). XPO achieved a PASI 50 score of 24 percent at V2 and 52 percent at V3 compared to CB (0% at V2 and 19% at V3). At V3, PGA was significantly reduced in both groups (<i>p</i>=0.003, XPO; <i>p</i>=0.001 CB). Both treatments significantly reduced itching at V2 (<i>p</i>=0.001, XPO; <i>p</i>=0.003, CB) and V3 (<i>p</i>=0.001, XPO; <i>p</i>=0.0005, CB).</p><p><strong>Conclusion: </strong>XPO showed similar efficacy to CB, significantly reducing disease severity, erythema, itching, induration, and scaling with an excellent tolerability profile.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3","pages":"12-17"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140145038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Tips for Non-Invasive Cosmetic Procedures in Skin of Color Patients. 有色人种无创美容手术临床小贴士。
Q2 Medicine Pub Date : 2024-03-01
Archana M Sangha
{"title":"Clinical Tips for Non-Invasive Cosmetic Procedures in Skin of Color Patients.","authors":"Archana M Sangha","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3-4 Suppl 1","pages":"S24-S25"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics. 股癣的治疗方案:疗效、副作用、依从性、经济考量和伦理。
Q2 Medicine Pub Date : 2024-03-01
Faraz Yousefian, Ciaran Smythe, Haowei Han, Boni E Elewski, Mark Nestor

Background: Onychomycosis is a fungal infection of the nail unit that affects a large patient population globally. Onychomycosis, or tinea unguium, has a benign chronic clinical course; however, it can cause complications in certain patient populations suffering from diabetes and peripheral vascular disease. As nails grow slowly, onychomycosis requires a lengthy treatment plan, and choosing appropriate treatments can be challenging. There are a variety of treatment modalities available for patients including topical, oral, laser, light therapy, procedures such as avulsion and matrixectomy, supplements, over-the-counter medication, and plasma therapy that can be used as monotherapy or in combination for patient satisfaction.

Objective: We sought to review treatment options for onychomycosis, taking into consideration the efficacy, side effect profiles, practicality of treatment (adherence), and costs to help healthcare providers offer ethically appropriate treatment regimens to their patients.

Methods: A literature search was conducted using electronic databases (PubMed, Embase, Medline, CINAHL, EBSCO) and textbooks, in addition to the clinical experiences of the authors and other practitioners in treating onychomycosis, and a summary of the findings are presented here.

Results: Although topical (efinaconazole, tavaborole, ciclopirox), oral (terbinafine, itraconazole), and laser (1064nm Nd:YAG lasers, both short-pulsed and Q-switched lasers, carbon dioxide lasers, and the diode 870, 930nm) are the current Food and Drug Administration (FDA)-approved treatments for onychomycosis, they are just a fraction of available treatment options. New and emerging therapies including new topical and oral medications, combination therapy, photodynamic light therapy, procedural, supplements, over-the-counter medication, and plasma therapy are discussed in our review.

Discussion: Onychomycosis has high reinfection and recurrence rates, and the treatment remains challenging as treatment selection involves ethical, evidence-based decision-making and consideration of each individual patient's needs, adherence, budget, the extent of quality of life discomfort, and aesthetic goals, independent of potential financial benefits to the clinicians.

背景:甲癣是指甲部位的真菌感染,影响着全球众多患者。甲癣是一种良性的慢性临床病程,但在某些患有糖尿病和外周血管疾病的患者中可能会引起并发症。由于指甲生长缓慢,甲癣需要一个漫长的治疗计划,而选择适当的治疗方法可能具有挑战性。目前有多种治疗方法可供患者选择,包括外用药、口服药、激光、光疗、撕脱术和基质切除术等手术、补充剂、非处方药和血浆疗法,这些方法可以作为单一疗法使用,也可以联合使用,以达到患者满意的效果:我们试图对癣菌病的治疗方案进行审查,同时考虑到疗效、副作用、治疗的实用性(依从性)和成本,以帮助医疗服务提供者为患者提供符合道德规范的治疗方案:方法:利用电子数据库(PubMed、Embase、Medline、CINAHL、EBSCO)和教科书进行文献检索,此外还参考了作者和其他从业人员在治疗甲癣方面的临床经验,现将研究结果总结如下:尽管外用药(依非那唑、他伐伯醇、环丙哌唑)、口服药(特比萘芬、伊曲康唑)和激光(1064nm Nd:YAG 激光、短脉冲激光和 Q 开关激光、二氧化碳激光以及 870、930nm 二极管)是目前美国食品和药物管理局 (FDA) 批准的治疗甲癣的方法,但它们只是现有治疗方法的一小部分。我们在综述中讨论了新的和新兴的疗法,包括新的外用和口服药物、联合疗法、光动力疗法、程序疗法、补充剂、非处方药物和等离子疗法:股癣的再感染率和复发率都很高,治疗仍然具有挑战性,因为治疗方法的选择涉及道德、循证决策以及对每个患者需求、依从性、预算、生活质量不适程度和审美目标的考虑,与临床医生潜在的经济利益无关。
{"title":"Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics.","authors":"Faraz Yousefian, Ciaran Smythe, Haowei Han, Boni E Elewski, Mark Nestor","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Onychomycosis is a fungal infection of the nail unit that affects a large patient population globally. Onychomycosis, or tinea unguium, has a benign chronic clinical course; however, it can cause complications in certain patient populations suffering from diabetes and peripheral vascular disease. As nails grow slowly, onychomycosis requires a lengthy treatment plan, and choosing appropriate treatments can be challenging. There are a variety of treatment modalities available for patients including topical, oral, laser, light therapy, procedures such as avulsion and matrixectomy, supplements, over-the-counter medication, and plasma therapy that can be used as monotherapy or in combination for patient satisfaction.</p><p><strong>Objective: </strong>We sought to review treatment options for onychomycosis, taking into consideration the efficacy, side effect profiles, practicality of treatment (adherence), and costs to help healthcare providers offer ethically appropriate treatment regimens to their patients.</p><p><strong>Methods: </strong>A literature search was conducted using electronic databases (PubMed, Embase, Medline, CINAHL, EBSCO) and textbooks, in addition to the clinical experiences of the authors and other practitioners in treating onychomycosis, and a summary of the findings are presented here.</p><p><strong>Results: </strong>Although topical (efinaconazole, tavaborole, ciclopirox), oral (terbinafine, itraconazole), and laser (1064nm Nd:YAG lasers, both short-pulsed and Q-switched lasers, carbon dioxide lasers, and the diode 870, 930nm) are the current Food and Drug Administration (FDA)-approved treatments for onychomycosis, they are just a fraction of available treatment options. New and emerging therapies including new topical and oral medications, combination therapy, photodynamic light therapy, procedural, supplements, over-the-counter medication, and plasma therapy are discussed in our review.</p><p><strong>Discussion: </strong>Onychomycosis has high reinfection and recurrence rates, and the treatment remains challenging as treatment selection involves ethical, evidence-based decision-making and consideration of each individual patient's needs, adherence, budget, the extent of quality of life discomfort, and aesthetic goals, independent of potential financial benefits to the clinicians.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3","pages":"24-33"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Becker Nevus Syndrome: A Rare Entity but Important to Recognize. 贝克痣综合征:罕见但必须认识。
Q2 Medicine Pub Date : 2024-03-01
Noureddine Litaiem, Amel Chabbouh, Ines Chabchoub, Radhi Ben Naceur, Mourad Mokni, Faten Zeglaoui

Becker's nevus syndrome is defined by the association of a Becker nevus with homolateral breast hypoplasia or more rarely skeletal cutaneous or muscle deformities. Early diagnosis is important, especially in female patients to prevent and treat breast hypoplasia. We report two cases of Becker nevus syndrome with serious functional impairment and discuss possible treatment options.

贝克痣综合征(Becker's nevus syndrome)的定义是贝克痣与同侧乳房发育不良或骨骼皮肤或肌肉畸形有关。早期诊断非常重要,尤其是对女性患者,以预防和治疗乳房发育不良。我们报告了两例伴有严重功能障碍的贝克尔痣综合征病例,并讨论了可能的治疗方案。
{"title":"Becker Nevus Syndrome: A Rare Entity but Important to Recognize.","authors":"Noureddine Litaiem, Amel Chabbouh, Ines Chabchoub, Radhi Ben Naceur, Mourad Mokni, Faten Zeglaoui","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Becker's nevus syndrome is defined by the association of a Becker nevus with homolateral breast hypoplasia or more rarely skeletal cutaneous or muscle deformities. Early diagnosis is important, especially in female patients to prevent and treat breast hypoplasia. We report two cases of Becker nevus syndrome with serious functional impairment and discuss possible treatment options.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3","pages":"21-23"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating Common Ingredients Contained in Dietary Acne Supplements: An Evidence-Based Review. 评估膳食痤疮补充剂中的常见成分:基于证据的综述。
Q2 Medicine Pub Date : 2024-03-01
Toral Vaidya, Lauren Hoffman, Anne Chapas

Objective: Acne vulgaris is a common skin condition treated with various medications targeting different aspects of its pathogenesis. Though increasing in popularity, the United States Food and Drug Administration (FDA) does not evaluate the safety or efficacy of dietary supplements marketed for the treatment of acne, calling into question the veracity of their labels. This review aimed to assess the safety and effectiveness of ingredients in popular acne supplements.

Methods: A comprehensive review was conducted on 13 popular supplements marketed for acne, found through a Google search. Their ingredients, prices, ratings, and existing literature on efficacy and safety were analyzed. A literature review was performed regarding the most common ingredients contained in these supplements.

Results: The most common ingredients in acne supplements were probiotics, diindolylmethane (DIM), vitamin A, vitamin B complex, and zinc. Despite the increasing popularity of dietary supplements, including those for skin health and acne, the absence of FDA regulation and evidence-based data raises concerns about their safety and efficacy. The safety of acne supplement ingredients raises significant worries, with reported cases of thrombotic events and adverse effects, even during pregnancy. The lack of standardized labeling and clear dosing information further complicates the understanding and potential risks of these supplements. Additionally, there is a potential for interactions with other medications, yet this information is often not provided on the product labels.

Limitations: A Google search was used to identify popular acne supplements. Search engine algorithms determine the ranking and presentation of results based on various factors, such as popularity, keywords, as well as user preferences and location, thus posing a potential sampling bias.

Conclusion: It is crucial to exercise caution and prioritize evidence-based information when counseling patients regarding the use of acne supplements.

目的:寻常痤疮是一种常见的皮肤病,针对其发病机理的不同方面可使用各种药物进行治疗。尽管痤疮越来越流行,但美国食品和药物管理局(FDA)并未对市场上销售的用于治疗痤疮的膳食补充剂的安全性和有效性进行评估,这使人们对其标签的真实性产生了怀疑。本综述旨在评估流行的痤疮补充剂成分的安全性和有效性:方法:通过谷歌搜索,对市场上 13 种流行的痤疮补充剂进行了全面审查。分析了这些保健品的成分、价格、评级以及有关功效和安全性的现有文献。此外,还对这些保健品中最常见的成分进行了文献综述:结果:痤疮补充剂中最常见的成分是益生菌、二吲哚甲烷(DIM)、维生素 A、复合维生素 B 和锌。尽管膳食补充剂(包括用于皮肤健康和痤疮的膳食补充剂)越来越受欢迎,但由于缺乏食品及药物管理局的监管和循证数据,人们对其安全性和有效性表示担忧。痤疮补充剂成分的安全性引起了人们的极大担忧,据报道,甚至在怀孕期间也有血栓事件和不良反应的案例。由于缺乏标准化标签和明确的剂量信息,使人们对这些保健品的了解和潜在风险变得更加复杂。此外,这些保健品还有可能与其他药物发生相互作用,但产品标签上往往没有提供这方面的信息:限制:使用谷歌搜索来确定流行的痤疮补充剂。搜索引擎算法会根据各种因素(如流行度、关键词以及用户偏好和位置)来决定搜索结果的排名和呈现方式,因此可能会造成抽样偏差:结论:在向患者提供有关使用痤疮补充剂的咨询时,谨慎行事并优先考虑循证信息至关重要。
{"title":"Evaluating Common Ingredients Contained in Dietary Acne Supplements: An Evidence-Based Review.","authors":"Toral Vaidya, Lauren Hoffman, Anne Chapas","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Acne vulgaris is a common skin condition treated with various medications targeting different aspects of its pathogenesis. Though increasing in popularity, the United States Food and Drug Administration (FDA) does not evaluate the safety or efficacy of dietary supplements marketed for the treatment of acne, calling into question the veracity of their labels. This review aimed to assess the safety and effectiveness of ingredients in popular acne supplements.</p><p><strong>Methods: </strong>A comprehensive review was conducted on 13 popular supplements marketed for acne, found through a Google search. Their ingredients, prices, ratings, and existing literature on efficacy and safety were analyzed. A literature review was performed regarding the most common ingredients contained in these supplements.</p><p><strong>Results: </strong>The most common ingredients in acne supplements were probiotics, diindolylmethane (DIM), vitamin A, vitamin B complex, and zinc. Despite the increasing popularity of dietary supplements, including those for skin health and acne, the absence of FDA regulation and evidence-based data raises concerns about their safety and efficacy. The safety of acne supplement ingredients raises significant worries, with reported cases of thrombotic events and adverse effects, even during pregnancy. The lack of standardized labeling and clear dosing information further complicates the understanding and potential risks of these supplements. Additionally, there is a potential for interactions with other medications, yet this information is often not provided on the product labels.</p><p><strong>Limitations: </strong>A Google search was used to identify popular acne supplements. Search engine algorithms determine the ranking and presentation of results based on various factors, such as popularity, keywords, as well as user preferences and location, thus posing a potential sampling bias.</p><p><strong>Conclusion: </strong>It is crucial to exercise caution and prioritize evidence-based information when counseling patients regarding the use of acne supplements.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3","pages":"34-41"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diplopia Secondary to Neurotoxin Injections: Prevention, Diagnosis, and Management. 继发于神经毒素注射的复视:预防、诊断和处理。
Q2 Medicine Pub Date : 2024-03-01
Tara Delle Chiaie
{"title":"Diplopia Secondary to Neurotoxin Injections: Prevention, Diagnosis, and Management.","authors":"Tara Delle Chiaie","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3-4 Suppl 1","pages":"S30-S36"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tick Bite Alopecia in an Adult Female Patient. 一名成年女性患者被蜱虫叮咬后出现脱发。
Q2 Medicine Pub Date : 2024-03-01
Nathaniel Schaefer, Rania Agha

Ticks are well-known vectors for transmitting disease and cause a variety of cutaneous manifestations to their afflicted host. Tick bite alopecia serves as a lesser-known illustration of this phenomenon, as few cases are documented in the literature. Scarring and nonscarring forms of tick-induced alopecia are described, with the latter being more common. This case highlights an adult female patient who developed a localized oval zone of midparietal scalp hair loss two months after the detection and removal of several ticks on her scalp. The chronicled events, clinical findings, and histopathology results further confirm a particular pattern of manifestation for tick bite alopecia. This case illustrates the importance of recognizing and considering tick bites as a possible cause of focal hair loss, given a similar presentation and historical account.

众所周知,蜱虫是传播疾病的载体,会给受感染的宿主带来各种皮肤症状。蜱虫叮咬性脱发是这种现象中鲜为人知的一种,因为文献中记载的病例很少。蜱虫引起的脱发有瘢痕和非瘢痕两种形式,后者更为常见。本病例重点描述了一名成年女性患者在发现并清除头皮上的几只蜱虫两个月后,出现局部椭圆形的顶中叶头皮脱发。所记录的事件、临床发现和组织病理学结果进一步证实了蜱虫叮咬性脱发的特殊表现模式。该病例说明,鉴于类似的表现形式和历史记录,认识到蜱虫叮咬可能是局灶性脱发的原因并将其视为一种可能的原因非常重要。
{"title":"Tick Bite Alopecia in an Adult Female Patient.","authors":"Nathaniel Schaefer, Rania Agha","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ticks are well-known vectors for transmitting disease and cause a variety of cutaneous manifestations to their afflicted host. Tick bite alopecia serves as a lesser-known illustration of this phenomenon, as few cases are documented in the literature. Scarring and nonscarring forms of tick-induced alopecia are described, with the latter being more common. This case highlights an adult female patient who developed a localized oval zone of midparietal scalp hair loss two months after the detection and removal of several ticks on her scalp. The chronicled events, clinical findings, and histopathology results further confirm a particular pattern of manifestation for tick bite alopecia. This case illustrates the importance of recognizing and considering tick bites as a possible cause of focal hair loss, given a similar presentation and historical account.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3-4 Suppl 1","pages":"S21-S22"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical and Aesthetic Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1